Online inquiry

IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7068MR)

This product GTTS-WQ7068MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FAP gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001291807.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2191
UniProt ID Q12884
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7068MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7442MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ13638MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ4799MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BT 5/9
GTTS-WQ7469MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ13498MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ2376MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 102
GTTS-WQ11234MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ6000MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW